Latest Period
Q1 2026
Security Snapshot
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) Institutional Ownership
CUSIP: M47238148
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
14
Shares (Excl. Options)
145,755
Price
$0.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Symbol
- GLMD on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 145,755
- Total 13F value
- $71,192
- Portfolio coverage rank
- 0%
- Share change
- -75,605
- Value change
- -$45,145
- Number of holders
- 14
- Shares outstanding
- 5,591,387
- SEC-reported price per share
- $0.59
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share is tracked under CUSIP M47238148.
- 14 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 16 to 14 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $166,356 to $71,192.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 14 institutions filings for Q1 2026.
Security key
M47238148
Latest holder period
Q1 2026
13F holders
14
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
GLMD full holder history
Galmed Pharmaceuticals Ltd. SEC filings
Galmed Pharmaceuticals Ltd. company facts
Galmed Pharmaceuticals Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M47238148:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
GLMD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. | 3.1% | -57% | $346,666 | 173,333 | 0% | CVI Investments, Inc. | 30 Sep 2025 | |
| Baharaff Allen | 2.6% | $60,455 | 44,128 | Allen Baharaff | 31 Dec 2024 |
As of 31 Mar 2026, 14 institutional investors reported holding 145,755 shares of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD). This represents 2.6% of the company’s total 5,591,387 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 145,755 | $71,192 | -$45,145 | $0.49 | 14 |
| 2025 Q4 | 221,660 | $166,356 | +$111,011 | $0.75 | 16 |
| 2025 Q3 | 72,824 | $102,011 | -$18,462 | $1.38 | 13 |
| 2025 Q2 | 75,987 | $140,174 | +$46,243 | $1.86 | 14 |
| 2025 Q1 | 55,876 | $80,439 | +$15,875 | $1.44 | 12 |
| 2024 Q4 | 44,767 | $142,806 | +$124,943 | $3.19 | 11 |
| 2024 Q3 | 5,585 | $38,313 | +$38,306 | $6.86 | 9 |